Pharmacological Researching Of TB, A Novel Nonthiazolidinedione Drug

TB, a new compound, was studied following the director of the FDA in this paper. By using the clinical drug rosiglitazone as a positive contro, TB was demonstrated in different animal models to prove to be a novel nonthiazolidinedione drug. The studies were including all of the follows.1. By using Balb/C mice, TB significantly decreased the fasting blood glucose lever of Balb/C mice(P<0.05), decreased the fasting plasma insulin lever of female Balb/C mice(P<0.05), but not changed the fasting plasma insulin lever of male Balb/C mice(P>0.05).2. By using male obese Zucker (fa/fa) rats, TB significantly decreased the fasting plasma insulin lever, plasma triglycerides and FFA lever of male obese Zucker (fa/fa) rat(sP<0.05). Through hyperinsulinemic-euglycemic clamps and HE dyeing, demonstrated that this compound significantly improves insulin sensitivity(P<0.05), also improves the hypertrophy and hyperplasia of the islets of Langerhans.3. By using streptozotocin and diet induced diabetes rats, TB significantly decreased the fasting blood glucose lever of type 2 Diabetes rats(P<0.05), but not changed the blood glucose lever of type 1 Diabetes rats(P>0.05). 4. In order to improve the bioavailability of oral drug, we produced floating tablets, whose bioavailability could reach 7.81% in pharmacokinetics screening research. Comparing with the blood concentration of the compound in SD rats, the Tmax & Cmax and the bioavailability of floating tablets were significantly increased, and the aim of control-release was achieved.Overall, all of these studies demonstrate that TB is a novel nonthiazolidinedione drug, just like the clinical drug rosiglitazone, can improve the insulin sensitivity, decrease the fasting blood lever, and influence the fatty metabolism.